Investment case
Intellia Therapeutics, Inc.
NTLA · 5 developments mapped · last assessed 2026-09-12
Market Ontology has mapped 5 macro, policy, and market developments to Intellia Therapeutics, Inc. since 2026-09-09. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for NTLA yet, so no modelled value is shown. The NTLA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run NTLA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.
· Moves investor perception of gene editing platform risk, ability to raise capital
- Open question
Cellectis Schedules September 14 Business and CAR T Pipeline Update
Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space.
· Moves sector wide investor sentiment for gene editing technologies, perceived regulatory environment for gene editing
What changed, by assumption
- 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
- 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
- 2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline Update
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
- 2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-15 | Revenue | Bullish | Positive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support potential U.S. launch in 1H 2027. | 0.90 |
| 2026-06-15 | Revenue | Bullish | Positive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support future commercial launch in 2027. | 0.90 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | watch | 1-5d | 0.30 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Bullish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Bullish | 3-12m | 0.30 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Bullish | 1-3m | 0.30 |
| 2026-09-09 | CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M | Bullish | 3-12m | 0.40 |